MIM
ZVRA icon

Monashee Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

Monashee Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-150,000
Closed -$1.04M – 105
2024
Q3 		$1.04M Buy
+150,000
New +$1.02M 0.11% 96

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Monashee Investment Management's ZVRA Position: Q4 2024 in Review

Monashee Investment Management sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 150,000 shares — an estimated $1.04M sold.

Monashee Investment Management first reported a position in ZVRA in Q3 2024 and held it in 1 quarter. The position peaked at $1.04M in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

  • Monashee Investment Management reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Monashee Investment Management sold 150,000 Zevra Therapeutics shares in Q4 2024, an estimated $1.04M.
  • Monashee Investment Management first reported a position in Zevra Therapeutics in Q3 2024 and held it in 1 quarter.
  • Monashee Investment Management's Zevra Therapeutics position peaked at $1.04M in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Monashee Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.